Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $74

Wells Fargo analyst Eva Fortea Verdejo maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $57 to $74.